Stem Cell Research Institute

K-Stemcell, formerly known as RNL Bio, is a South Korean biotechnology company specializing in the development of autologous adipose-derived mesenchymal stem cell (AdMSC) therapies. The company operates primarily through its Stem Cell Research Institute (SCRI), which focuses on pioneering regenerative medicine for degenerative and intractable diseases. Its lead clinical candidate, JointStem, is a Phase 3 stem cell therapy designed to treat knee osteoarthritis through a single intra-articular injection. K-Stemcell's broader pipeline includes AstroStem for Alzheimer's disease and various programs targeting spinal cord injuries and autoimmune disorders. The company is recognized for its proprietary technology in isolating and mass-culturing high-purity stem cells from a patient's own fat tissue.